Analysts Insights on Fresenius Medical Care AG & Co. (NYSE:FMS)


[BusinessWire] Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) in anticipation of Winter Storm Juno – which is threatening much of the Northeast with blizzard conditions and up to three feet of snow – Fresenius Medical Care North America (FMCNA), the nation’s leading network of dialysis facilities, has activated its Incident Command Team to begin implementing plans to ensure continued patient care in the areas affected by the storm.

While storms and other natural disasters can be inconvenient and even life-threatening for entire communities, they pose an especially serious health threat to dialysis patients whose treatments are delayed by flooding, electrical power outages or an inability to access their normal treatment locations.. ……. Read the full article here.


Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) [Trend Analysislast released quarterly earnings on November 4th for the period ending September 30th 2014. The company reported actual earnings per share of $0.45 against Zack’s Research estimate of $0.44. This represents a 2.27% (0.01) surprise upside to the expected number.

The average broker recommendation according to Zacks is 2.38 based on 8 recommendations. On a consensus basis, analysts have a short term target price of $39.25 and expect a long term growth rate of 8.40%. Out of 265 companies within the Medical Instruments industry, the company sits at 99. Zacks gives a current quarter EPS estimate of 0.49 and a Hold rating of 3 which is based on short term performance over the next one to three months. Of the companies included in the Zack’s consensus rating, 3 rate the stock a Strong Buy and 4 see it as a Hold.

About Fresenius Medical Care AG & Co

Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS), a kidney dialysis company, provides renal dialysis products and services. It offers dialysis treatment, and related laboratory and diagnostic services through its network of 3,250 outpatient dialysis clinics in approximately 45 countries worldwide; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the U.S. for the hospitalized ESRD patients and for patients suffering from acute kidney failure. The company also provides pharmacy services, such as delivery and supply of renal medications to patients at homes or to dialysis clinics directly; vascular access surgery services; and manufactures and distributes products for the treatment of end-stage renal disease (ESRD).

Discussion2 Comments

    • Excellent comment David. It certainly creates opportunities in other preventative companies. Perhaps a long short trade even?

Leave A Reply